ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback